Platform Technology: Is it possible to reduce vaccine development time?

An IABS webinar: Thursday, February 18, 2021 from 14 :00 – 16 :30 CET

Testimonials from J&J, Curevac and BioNtech

Round table discussion with Industry, EMA, FDA, Health Canada, PEI, WHO…

Agenda

Platform Technology: what are the first experiences from different players who were allowed by the authorities to use data from other programs in a platform technology approach in order to shorten the development time.

Webinar Registration link : https://www.iabs.org/platform-technology-webinar.

Use the buttons below if you would like to share this info :

ZAPI Stakeholders Final Conference
February 4-5, 2021
A Virtual Meeting


INFORMATION ABOUT AND REGISTRATION FOR THE MEETING HERE


In March 2015, IMI  (Innovative Medicine Initiative - https://www.imi.europa.eu) launched ZAPI (Zoonotic Anticipation and Preparedness Initiative) to set up methodologies and platform technologies that would be ready to put into production for vaccines and neutralizing monoclonal antibodies to efficiently counter emerging or remerging zoonotic viruses.

“The objective is to demonstrate that we can deliver on these platforms, using three different prototype models of diseases that occurred in the recent past and which are zoonotic in nature.” The viruses that [have been] used as models are Middle East respiratory syndrome coronavirus (MERS-CoV); Schmallenberg virus; and Rift Valley Fever virus’. IMI ZAPI Interview

Six years later, the ZAPI project has made great strides in vaccine and antibody design, and new approaches for achieving the “surge manufacturing capacity” objective.

The Final Stakeholders Global Meeting will present an overview of the main findings and key learnings from the ZAPI project partnership’s experience for improving our One Health preparedness status for facing effectively future pandemics.

The ZAPI project benefits from the assistance and financial support of
IMI and the European Commission, and in-kind contributions from EFPIA partners.

Use the buttons below if you would like to share this info :

Cross learning experience human and animal vaccine licensure
based on technology platforms

A Joint CEPI / IABS-EU Workshop

Registration and information about the Meeting

 

MEETING RESCHEDULED


The difficult situation we are facing currently in Europe
and the uncertainties concerning the evolution

of the Covid-19 pandemic
has led us to once again postpone
the CEPI / IABS-EU Workshop.

More information will be posted shortly.

Use the buttons below if you would like to share this info :

Autogenous Vaccines:
Quality of production and movement in a common market

Ludwig-Maximilians-University Munich

registration and information about the meeting

Use the buttons below if you would like to share this info :

Maintaining the quality of vaccines through the use of references standards
Current challenges and future opportunities

Due to the uncertainties concerning the evolution
of the Covid-19 pandemic, the meeting is once again rescheduled
and will now take place on

June 8-9, 2021

 Registration and information about the meeting

Use the buttons below if you would like to share this info :

International Alliance for Biological Standardization


Twitter Feed

Examples of networks to address transdisciplinary issues related to infectious disease prevention and vaccine devel… https://t.co/HmhZmZFHn9
#IABS 65 conference on Infectious diseases, LYON. John Edmunds (London School of Tropical Hygiene & Medicine): Real… https://t.co/TYd0mOS3zC
Follow IABS_global on Twitter

Contact Info

IABS, Rue de la Vallée, 3
CH-1204 Geneva

Switzerland
+ 41 22 301 10 36
+ 41 22 301 10 37
This email address is being protected from spambots. You need JavaScript enabled to view it.